To further explore the relationships between responses to inhibition of BCR, mTOR, and MEK in CLL, we exposed primary CLL samples (6 M-CLL and 6 U-CLL) to ibrutinib, idelalisib, selumetinib, and everolimus and compared the drug-induced gene-expression changes (Supplemental Figure 9C). The gene discussed is MTOR; the disease is B-cell chronic lymphocytic leukemia.